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Fecal microbiota transplantation has proven to be an effective treatment for infections
with the gram-positive enteropathogen Clostridium difficile. Despite its effectiveness,
the exact mechanisms that underlie its success are largely unclear. In this review, we
highlight the pleiotropic effectors that are transferred during fecal microbiota transfer and
relate this to the C. difficile lifecycle. In doing so, we show that it is likely that multiple
factors contribute to the elimination of symptoms of C. difficile infections after fecal
microbiota transplantation.
Keywords: fecal microbiota transplant, Clostridium difficile infection, short chain fatty acids, bile acids, sialic
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INTRODUCTION
Fecal microbiota transplantation (FMT), the transfer of (processed) fecal material from healthy
donors to patients, has been documented already over 1700 years ago for the treatment
of gastrointestinal illness in humans. The Chinese scholar Ge Hong used fecal suspension
administered orally to treat severe diarrhea; the 16th century scientist Li Shizhen referred to
such suspensions as “yellow soup” (Zhang et al., 2012). Similarly, during World War II, soldiers
stationed in North-Africa took up the practice of treating dysentery using camel dung, after
observing locals do so (Lewin, 1999). Though in either case the rationale for treatment was
unknown, anecdotal reports of successful treatment triggered a renewed scientific interest in the
middle of the 20th century.
The first description of a fecal enema as treatment in modern medical literature dates from 1958,
when four patients with pseudomembranous colitis were treated (Eiseman et al., 1958). At that time
not identified yet as such, the major causative agent of pseudomembranous colitis is Clostridium
difficile, a gram-positive, spore forming, obligate anaerobic bacterium (Hall and O’Toole, 1935;
George et al., 1978; Larson et al., 1978; Smits et al., 2016). It was originally identified as part of
the normal gut microbiota of healthy infants in 1935 (Hall and O’Toole, 1935) and was recently
reclassified as Clostridioides difficile, based on phenotypic, chemotaxonomic and phylogenetic
analyses (Lawson et al., 2016). 16S rRNA gene sequence analysis showed that the closest relative
is Clostridium mangenotii (Lawson et al., 2016). Ground-breaking work in the 70’s established that
C. difficile was a transmissible pathogen that produced toxin(s) capable of inducing gastrointestinal
Frontiers in Microbiology | www.frontiersin.org 1 June 2018 | Volume 9 | Article 1242
fmicb-09-01242 June 8, 2018 Time: 18:58 # 2
Baktash et al. Mechanisms of FMT in CDI
disease in various animals (Chang et al., 1978; Bartlett,
2009). C. difficile infection (CDI) is believed to be triggered
by antibiotics which disrupt the normal microbiota enabling
the outgrowth of toxin-producing C. difficile (Dethlefsen and
Relman, 2011; Rea et al., 2011; Hensgens et al., 2012; Keller and
Kuijper, 2015).
The first-line therapy of CDI according the European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guideline is with the prodrug metronidazole, that
is converted by anaerobic bacteria into nitroso radicals that
exert an antimicrobial effect (Debast et al., 2014). However,
metronidazole appears less effective compared with vancomycin
and fidaxomicin in inducing initial cure (Johnson et al., 2014;
Ooijevaar et al., 2018). As a result, vancomycin and fidaxomicin
are recommended in the 2017 update of the guidelines of the
Infectious Diseases Society of America and Society for Healthcare
Epidemiology of America, even for mild and first occurrence
CDI (McDonald et al., 2018). Nevertheless, the risk of recurrence
after treatment within 8 weeks is 15–25% and rises to 40–65% in
patients suffering from multiple recurrences (Fekety et al., 1997;
Cornely et al., 2012; Johnson et al., 2014; Keller and Kuijper,
2015).
16S rRNA gene sequence analysis of gut microbiota of patients
with an initial or recurrent CDI showed that patients with
recurrent disease showed a highly variable bacterial composition
in comparison with the normal predominance of Bacteroidetes
and Firmicutes. Furthermore, patients with recurrent CDI
showed lower species richness compared with patients with an
initial episode of CDI patients and control subjects (Chang
et al., 2008; Seekatz et al., 2016). This suggested that modulating
microbiota composition could be key in the treatment of
recurrent CDI.
The first randomized control trial using FMT to treat
recurrent CDI (16 patients in the FMT arm versus 26 in the
control arms) demonstrated a remarkable efficacy (van Nood
et al., 2013), which was confirmed in multiple independent
analyses. For instance, the meta-analysis by Quraishi and co-
workers, that included seven randomized controlled trials (RCTs)
and 30 case series, showed that FMT is more effective than
vancomycin in resolving recurrent and refractory CDI with a
relative risk of 0.23 and a clinical resolution of 92% (Quraishi
et al., 2017). The meta-analysis by Moayyedi and co-workers
included ten RCTs with a total of 657 patients with C. difficile-
associated diarrhea and demonstrated that FMT was significantly
more effective compared with placebo or vancomycin treatment,
with a relative risk of 0.41 (Moayyedi et al., 2017). However, great
heterogeneity exists among the included studies with respect to
donor feces volume, FMT preparations, route of administration,
pre-treatment and numbers of FMTs (Moayyedi et al., 2017;
Quraishi et al., 2017; Terveer et al., 2018). After FMT, patients
show an increase in microbiota diversity, reaching levels that are
observed in healthy donors (van Nood et al., 2013; Fuentes et al.,
2017). Taken together, the data show that for patients suffering
from multiple recurrent CDI, FMT is a highly effective treatment
(Ooijevaar et al., 2018) and FMT is now indicated in therapeutic
guidelines for this group of patients (McDonald et al., 2018).
Recommended treatment modalities and FMT procedures have
been reviewed elsewhere (Cammarota et al., 2017; Terveer et al.,
2017b; Woodworth et al., 2017; Panchal et al., 2018).
Multiple recurrent C. difficile infections remain the prime –
and arguably only - example for which there is a consistent body
of evidence for treatment by FMT and for which FMT is indicated
as treatment strategy (Smits et al., 2016; McDonald et al., 2018;
Ooijevaar et al., 2018). Yet, what is it in the donor material
that results in the elimination of symptoms, and/or detectable
presence of the pathogen? Fecal suspensions commonly used for
FMT contain a plethora of abiotic and biotic factors. In this
Review, we summarize our understanding of the possible active
constituents in donor fecal material in relation to the C. difficile
lifecycle (Figure 1A).
COLONIZATION RESISTANCE
The first step in the establishment of an infection is colonization
of a host with pathogenic C. difficile bacteria. Such colonization
can result in asymptomatic carriership, or in disease (Eyre et al.,
2013; Terveer et al., 2017a; Crobach et al., 2018). The onset of
disease can be triggered through a disruption of the healthy
microbiota due to exogenous factors such as antimicrobials
(Britton and Young, 2014; Keller and Kuijper, 2015; Smits
et al., 2016). In the early 1960’s, such antibiotic associated
susceptibility to infection was also observed for Salmonella
enterica (Bohnhoff and Miller, 1962). The hypothesis that a
stable microbial community can prevent colonization and/or
outgrowth of pathogens has become known as colonization
resistance (Lawley and Walker, 2013). In its simplest view, FMT
replenishes the microbial diversity that is lost after antimicrobial
treatment and therefore confers colonization resistance against
C. difficile. Though intuitively it is appealing that a dense
microbial community exerts this effect, it should be noted that
colonization resistance is as poorly defined as FMT. Microbial
and immunological factors that play a role in colonization
resistance (Lawley and Walker, 2013) are also likely to play a
role in the success of FMT. Microbiota-immune interactions
have been reviewed elsewhere (Belkaid and Hand, 2014; Khoruts
and Sadowsky, 2016), and are not in the scope of this review.
Here, we focus on the transferable components of a fecal
suspension.
PRIMARY AND SECONDARY BILE ACIDS
If we look beyond numbers, are there any specific mechanisms
that might contribute to the efficacy of FMT? What small
molecules have been shown to affect the lifecycle of C. difficile?
Spores are essential for the transmission of C. difficile between
hosts and persistence in the (hospital) environment (Deakin et al.,
2012; Paredes-Sabja et al., 2014). Upon passing the stomach, bile
acids induce germination of C. difficile spores (Francis et al., 2013;
Kochan et al., 2017) (Figure 1B).
Bile acids promote intestinal absorption and transport of
lipids, nutrients and vitamins, but also serve a broad range of
regulatory functions throughout the body (Chiang, 2009). The
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FIGURE 1 | Selected mechanisms by which the gut microbiota, metabolites and peptides can affect C. difficile. (A) The lifecycle of C. difficile. Spores germinate into
vegetative cells, which then proliferate and start to produce toxins. The lifecycle is completed by the formation of spores from vegetative cells again. (B) A simplified
overview of the effects of bile acid metabolism on C. difficile. Secondary bile acids are formed from primary bile acids via 7α-dehydroxylation by gut bacteria. Primary
bile acids promote germination of spores into vegetative cells, while secondary bile acids generally inhibit this process. Secondary bile acids can inhibit toxin
production. (C) A simplified view of the effects of specific nutrients on C. difficile. Dietary fibers are fermented by the gut microbiota and short-chain fatty acids
(SCFAs) are released. Succinate can stimulate C. difficile expansion, whereas other SCFAs potentially inhibit growth. Certain bacterial species in the gut cleave
sialidated carbohydrates, releasing sialic acid that stimulates C. difficile expansion. (D) Schematic view of naturally occurring antimicrobial factors. The human gut
has a high abundance of microbial species, some of which produce bacteriocins that are bacteriostatic or bactericidal for C. difficile. Certain bacteriophages present
in the gut microbiota use C. difficile as a host. Antimicrobial peptides (AMP) are produced by host cells that inhibit C. difficile growth and inhibit toxin activity.
primary bile acids, cholic acid and chenodeoxycholic acid, are
synthesized in the liver from cholesterol in a multi-step process
and are conjugated to either glycine or taurine (Chiang, 2009).
They are hydrophobic and conjugation increases their solubility
(Staley et al., 2017). After food intake, bile acids are released
into the duodenum and are reabsorbed by active transport in
the distal ileum. This enterohepatic circulation has an overall
recovery efficiency of ∼95% (Chiang, 2009). The secondary
bile acids, deoxycholic acid and lithocholic acid, are formed
via 7α-dehydroxylation by gut bacteria from bile acids that are
not reabsorbed (Chiang, 2009). These bacteria are members of
the Lachnospiraceae and Ruminococcaceae families and include
Clostridium scindens (Weingarden et al., 2014; Buffie et al., 2015).
Recirculated secondary bile acids are conjugated to glycine and
taurine similar to primary bile acids (Chiang, 2009).
Bile acids can directly or indirectly influence the composition
of the gut microbiota. Several studies demonstrated that bile acids
have direct antimicrobial effects by damaging cell membranes
and DNA through oxidative and pH stress (Kakiyama et al.,
2013; Staley et al., 2017). There is a varying degree of
bile resistance, tolerance and susceptibility even within single
bacterial species (Staley et al., 2017). Bile acids can also regulate
the gut community structure indirectly, as shown for cholic
acid (Islam et al., 2011). Supplementation of the diet with
cholic acid resulted in an increase of Firmicutes, a group that
encompasses bacteria capable of 7α-dehydroxylating cholic acid,
and decrease of Bacteroidetes (Islam et al., 2011; Ridlon et al.,
2013).
Bile acids in the gastrointestinal tract affect the growth of
C. difficile (Figure 1B). In vitro, primary bile acids generally
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stimulate germination, whereas secondary bile acids inhibit this
process (Francis et al., 2013; Paredes-Sabja et al., 2014; Thanissery
et al., 2017). The latter finding is recapitulated in a murine-
derived model where physiologically relevant concentrations
of primary and secondary bile acids where tested (Theriot
and Young, 2015). In this model, C. difficile was able to
germinate and grow in ileal an cecal content when secondary
bile acids were depleted, demonstrating that secondary bile acids
inhibit spore germination and growth (Theriot and Young,
2015).
Patients with CDI have an altered fecal bile acid composition
in the colon. For instance, secondary bile acids were higher in
fecal samples from controls compared to patients with CDI, and
primary bile acids were elevated in patients with recurrent disease
compared to those experiencing a first episode of CDI (Allegretti
et al., 2016).
Fecal microbiota transplantation treatment has a significant
effect on the bile acid composition. Pre-FMT fecal samples of
CDI patients show a shift in the balance between primary bile
acids and secondary bile acids, almost completely toward the
former, whereas post-FMT fecal samples contain predominantly
secondary bile acids, similar to donor samples (Weingarden
et al., 2014). A combination of pre-FMT bile acids induced
germination of C. difficile in vitro, whereas the post-FMT
combination did not. Likewise, pre-FMT bile acids did not
affect the vegetative growth of C. difficile, but bile acids from
post-FMT feces significantly reduced growth (Weingarden
et al., 2016b). Differences in bile acid composition are
likely the result of microbiota-dependent differences in bile
acid conversion. Indeed, the 7α-dehydroxylating intestinal
bacterium C. scindens was associated with resistance to
C. difficile infection (Buffie et al., 2015), and a simplified
12-species “oligo-mouse microbiota”(Oligo-MM12) that
represents the major murine intestinal bacterial phyla, but
is 7α-dehydroxylation deficient, fails to confer resistance to
CDI (Studer et al., 2016). Supplementation of the mice with
C. scindens normalized the intestinal bile acid composition
and impacted early colonization with C. difficile, but was
insufficient to prevent pathogenesis (Studer et al., 2016). It
is hypothesized that antibiotics might reduce the amount of
secondary bile acids by eliminating bile acid converting bacteria,
thereby increasing the propensity for CDI (Weingarden et al.,
2014).
However, it is important to note that a model where primary
bile acids strictly promote and secondary bile acids inhibit
C. difficile germination and vegetation might be oversimplified.
Physiological concentrations of the primary bile acids taurocholic
acid, cholic acid and higher concentrations of chenodeoxycholic
acid induced germination of spores, whereas physiological
concentrations of chenodeoxycholic acid did not (Weingarden
et al., 2016b) or even inhibited spore germination (Sorg
and Sonenshein, 2009, 2010; Theriot and Young, 2015). The
secondary bile acids deoxycholic acid and litocholic acid did
not induce germination of spores (Weingarden et al., 2016b),
in contrast to other studies which have shown that deoxycholic
acid can be a germinant for C. difficile (Wilson, 1983; Sorg and
Sonenshein, 2008).
Interestingly, recent work suggests that bile acids or bile acid-
derived molecules may also influence toxin-dependent effects.
In a small molecule screen, methyl cholate – but not cholate –
was identified as a compound that inhibits auto-processing and
receptor binding (Tam et al., 2015), leading to a reduction of
toxin-dependent epithelial damage. Deoxycholate (0.02%) was
found to inhibit toxin levels for some, but not all C. difficile strains
in vitro (Thanissery et al., 2017).
Collectively, the data above suggest that bile acids may be
an important component of an FMT (Weingarden et al., 2014)
and that modulation of bile acid composition may be a viable
therapeutic intervention (Buffie et al., 2015; Studer et al., 2016):
FMT may introduce bacteria that affect bile acid composition
and subsequently C. difficile germination and growth, or bile
acids already present in the donor material may directly influence
these processes. In support of the latter, it was reported that oral
ursodeoxycholic acid (a secondary bile acid) was successfully used
in conjunction with vancomycin to treat a patient with recurrent
CDI pouchitis (Weingarden et al., 2016a). Both mechanisms,
however, may not be mutually exclusive.
CARBOHYDRATES AND OTHER
NUTRIENTS
Upon germination, vegetative cells use the nutrients available
in the gut to proliferate. The nutritional requirements and
capabilities of C. difficile have been extensively studied (Hafiz
and Oakley, 1976; Karasawa et al., 1995; Scaria et al., 2014), but
our understanding of the nutrient availability in the gut lumen
in relation to C. difficile infection is limited. A metabolomic
analysis showed that colonization with C. difficile leads to shifts in
detectable metabolites and underscored the importance of amino
acids and other nutrient availability for C. difficile colonization
and pathogenesis (Fletcher et al., 2018).
In relation to CDI, some of the best characterized effects
concern the liberation of sialic acid (Figure 1C). The mammalian
host is protected from direct interaction with gut-dwelling
microbes due to a physical barrier of heavily glycosylated mucus
components produced by specialized cells in the intestinal
mucosa. The mucus consists of an inner layer and a “loose”
outer layer (Atuma et al., 2001). The outer layer can act
as an important source of nutrition for bacteria capable of
digesting its carbohydrate chains (Marcobal et al., 2013; Robinson
et al., 2017). These carbohydrate chains are often capped with
sialic acid, a 9-carbon-backbone monosaccharide that protects
them from enzymatic reactions of exo- and endoglycosidases.
Certain intestinal bacteria are able to remove sialic acids by
expressing sialidases (Marcobal et al., 2011; Robinson et al.,
2017). To protect sialic acids from these enzymatic actions they
are modified through O-acetylation. This modification takes
place in the inner mucus layer at the 7-O position of the
sialic acid. As the mucus matures and moves to the outer
layer the acetylation moves from the 7-O to the 9-O position.
Some intestinal bacteria encode O-acetyl esterases that can
remove the acetyl group, thus giving access to the sialidases
that can remove the sialic acids. The O-acetyl esterases can
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only remove 9-O- acetyl groups, but not 7-O- acetyl groups
(Robinson et al., 2017). Thus, the inner mucus layer is always
protected, whereas the outer layer can be a carbon source for
intestinal bacteria. Not all bacterial species contain all enzymes
required for digestion of complex carbohydrates. For example,
Bacteroides fragilis encodes both sialidase and O-acetyl esterase
activity, whereas Bacteroides thetaiotaomicron only has esterase
activity. Bacteria that lack sialidases and esterases themselves
can take advantage of the enzymatic activities provided by the
other members of the microbiota to access nutrients and gain
access to the epithelium (Marcobal et al., 2013; Robinson et al.,
2017).
Antibiotic treatment can alter the balance in the mucolytic
activities; elimination of species that efficiently scavenge sialic
acid allows antibiotic-resistant pathogens to profit from the free
sugars and expand rapidly as has been shown for both Salmonella
typhimurium and C. difficile (Ng et al., 2013). In gnotobiotic
mice colonized with sialidase-producing B. thetaiotaomicron, or
by exogenous dietary administration of free sialic acid, a rapid
expansion of the enteropathogens was observed. Colonization by
a sialidase-deficient mutant of B. thetaiotaomicron reduced the
levels of free sialic acid and impaired expansion of C. difficile
(Ng et al., 2013). In an in vitro model it was also observed
that other members of the microbiota compete more efficiently
than C. difficile for monomeric glucose, N-acetylglucosamine and
N-acetylneuraminic acid, in addition to sialic acid (Wilson and
Perini, 1988).
Dietary carbon sources have also been implicated in C. difficile
infection. Nosocomial outbreaks and sustained high infection
rates in the community can frequently be attributed to the
epidemic PCR ribotypes 027 and 078, respectively (Goorhuis
et al., 2008; Bauer et al., 2011; He et al., 2013; Smits et al.,
2016). Recently, it has been shown that both these PCR ribotypes
can use low concentrations of trehalose more efficiently as a
carbon source than non-epidemic types (Collins et al., 2018).
In 027 strains this is the result of a point mutation in the
trehalose repressor TreR that leads to stronger derepression in the
presence of trehalose. Strains of PCR ribotype 078 appear to have
acquired an extra gene cluster encoding a trehalose importer. The
introduction of trehalose into the food chain might have preceded
the expansion of the epidemic types, suggesting a causative effect
(Collins et al., 2018).
Besides affecting growth, nutrients are also known to affect
expression levels of the main virulence factors of C. difficile,
the major clostridial toxins A (TcdA) and B (TcdB) (Bouillaut
et al., 2015; Martin-Verstraete et al., 2016; Smits et al., 2016).
For instance, the addition of glucose to C. difficile growth
medium drastically reduces toxin gene expression (Dupuy and
Sonenshein, 1998; Oliveira Paiva et al., 2016) and amino acids
can both negatively and positively affect toxin levels (Yamakawa
et al., 1994; Karlsson et al., 1999). In line with the effects
observed for glucose, ethanolamine delays toxin production
in C. difficile, in contrast to other gut pathogens that use
ethanolamine as a virulence-inducing signal (Nawrocki et al.,
2018). Ethanolamine is a breakdown product of membrane-
derived phosphatidylethanolamine, which is abundant in the
gut and is increased during inflammatory responses. Mutants
of C. difficile that cannot utilize ethanolamine show enhanced
virulence in a hamster model of infection (Nawrocki et al., 2018),
that is exquisitely sensitive to levels of toxin A and B (Bakker et al.,
2014).
It should be noted that most of these studies were performed
in vitro, and it is largely unclear how the levels used in these
experiments relate to luminal levels in vivo. Nevertheless, there
is some recent evidence that dietary interventions can be relevant
for CDI. Defined nutrient diets, in particular low protein diets,
were found to increase survival of mice and reduce disease
severity (Moore et al., 2015). Also, C. difficile burden in mice with
humanized microbiota could be suppressed when the mice were
fed with microbiota accessible carbohydrates found in dietary
plant polysaccharides, whereas mice with diets deficient for such
carbohydrates show a persistent infection (Hryckowian et al.,
2018).
The effects of antimicrobials, nutrient availability, sensing
nutritional status and toxin production by C. difficile come
together in a recently formulated model (Hryckowian et al.,
2017). It was suggested that C. difficile expansion following
antibiotic treatment initially occurs without toxin production,
possibly due to the presence of readily metabolizable nutrient
sources such as glucose and sialic acid. After the expansion,
C. difficile may switch to toxin production, leading to a favorable
state of inflammation to inhibit competitors.
Considering the above, it is conceivable that the nutrient or
carbohydrate availability in donor material affects the efficacy
of FMT, either by affecting the (re)growth of C. difficile or by
suppressing toxin expression and thereby reducing symptoms.
However, these possible effects have not been systematically
investigated to date and further studies are required to determine
if nutrient variables should be monitored or adjusted in donor
material.
SHORT AND MEDIUM CHAIN FATTY
ACIDS
Above, we discussed the relevance of nutrient levels for the
growth and pathogenesis of C. difficile. Next, we want to extend
this, by focusing on a particular class of carbohydrates: the short
and medium chain fatty acids - monocarboxylic acids with a
carbohydrate chain length of 1 to 12 carbon atoms (Schonfeld
and Wojtczak, 2016) (Figure 1C). These compounds have gained
interest in the context of gastrointestinal disease due to their
immune-modulatory and antimicrobial effects (Maslowski et al.,
2009).
Short-chain fatty acids (SCFAs; chain length 1–6), are the main
products of dietary fibers that are fermented by anaerobic gut
bacteria and serve as substrates for energy metabolism (Roediger,
1980; den Besten et al., 2013). The most abundant SCFAs
are acetate, propionate and butyrate (den Besten et al., 2013;
Schonfeld and Wojtczak, 2016). Other common end-products of
primary fermenters are the organic acids succinate and lactate,
which are metabolized by other bacteria (Ferreyra et al., 2014).
In mice, SCFAs bind G-protein coupled receptor 43 (GPR43)
which results in resolution of inflammatory responses providing
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a link between immune and inflammatory responses, diet and the
metabolism of gut bacteria (Maslowski et al., 2009). Many SCFAs
can be associated with an improvement of gut barrier function
and also possess anti-inflammatory properties (Tedelind et al.,
2007; Chen et al., 2017).
C. difficile metabolizes succinate to butyrate, particularly
under antibiotic treatment or chemically induced diarrhea that
results in an abundance of succinate and a reduction of acetate
and butyrate (Ferreyra et al., 2014). A mutant C. difficile, deficient
in succinate utilization, and therefore butyrate production,
displays attenuated growth under both these conditions (Ferreyra
et al., 2014). Though succinate is generally not detected in a
healthy human gut, it was found that succinate accumulates in
pigs suffering from antibiotic associated diarrhea (Tsukahara and
Ushida, 2002). Succinate therefore may be depleted by cross-
feeding (i.e., taken up and metabolized) and antibiotic use may
perturb these interactions (Ferreyra et al., 2014).
Several studies have reported differences in SCFA producing
bacteria and/or SCFA levels between healthy subjects and CDI
patients: 16S rRNA gene analysis shows that butyrate producers,
such as Ruminococcaceae and Lachnospiraceae families, are
significantly reduced in CDI patients compared to controls
(Antharam et al., 2013; Song et al., 2013; Ling et al., 2014;
Lamendella et al., 2018). Concomitantly, increased levels of
succinate, lactate, formate producers such as Bacteroides spp.
were found (Antharam et al., 2013; Ling et al., 2014).
Short-chain fatty acid levels also appear to correlate with
colonization resistance against C. difficile in certain cases.
Mice treated for 2 weeks with cefoperazone are susceptible to
colonization by C. difficile and metabolomics analyses showed
reduced levels of acetate, propionate and butyrate compared to
non-treated mice (Theriot et al., 2014). Six weeks after cessation
of the antimicrobial treatment, colonization resistance was fully
restored and SCFA levels recovered, though not to the levels
observed in non-treated mice (Theriot et al., 2014). In earlier
work, colonization resistance in hamsters was also found to
coincide with high levels of SCFAs, that inhibit C. difficile growth
(Rolfe, 1984). Cecal SCFA levels increase in hamsters from day
1, and reach a maximum at 19 days. Hamsters are susceptible to
C. difficile colonization between days 4 and 15 and levels of SCFA
corresponding to day 16 onward are bactericidal to C. difficile
cultures in vitro (Rolfe, 1984).
The correlations between CDI and SCFAs have triggered
investigations to modulate CDI development and progression
through dietary interventions. Non-digestible oligosaccharides
(dietary fiber) are carbohydrates resistant to the effects of
gastrointestinal enzymes, but can be fermented to SCFAs by
members of the colonic microbiota. Indeed, the addition of
fiber to an in vitro model using fecal inoculums from pigs
leads to high levels of acetate, propionate and butyrate that
correlates with the expansion of anaerobic bacteria (May et al.,
1994). In an in vitro model that simulates the conditions of
the proximal part of the large intestine, the introduction of
C. difficile leads to a suppression of propionate production and
an increase in the branched-chain fatty acids isobutyrate and
isovalerate (van Nuenen et al., 2003). The addition of inulin, a
non-digestible oligosaccharide, reversed this effect and increased
the total amount of SCFAs by 50% (van Nuenen et al., 2003).
In another experiment, supplementation of in vitro cultures with
different oligosaccharides increased SCFA production and did
not result in detectable C. difficile toxin (Hopkins and Macfarlane,
2003). However, this was not the case during clindamycin
treatment, where supplementation led to a reduction in SCFAs
and conditions conducive for toxin production by C. difficile.
(Hopkins and Macfarlane, 2003)
Despite the evidence presented above, a role for SCFA in
control of CDI is not undisputed. No correlation was found
between a qualitative SCFA profile of fecal emulsion and its
ability to inhibit the growth of C. difficile in vitro (Borriello
and Barclay, 1986). Furthermore, in a gnotobiotic mouse model,
SCFAs alone did not affect colonization by C. difficile (Su
et al., 1987). More recently, partial restoration of colonization
resistance was reported when germ free mice were pre-colonized
with Lachnospiraceae, but not with E. coli (Reeves et al., 2012).
Though many Lachnospiraceae are SCFA producers (Scott et al.,
2014), no association between SCFA production and C. difficile
colonization levels was found (Reeves et al., 2012). Importantly,
neither a fecal filtrate (containing SCFA), nor SCFAs were able to
clear a C. difficile infection in mice (Lawley et al., 2012).
Medium chain fatty acids (MCFAs; with chain length 7–12) are
predominantly derived from triglycerides and phospholipids that
are ingested as part of plant oils and milk products (Schonfeld
and Wojtczak, 2016). MCFAs can have antimicrobial activity,
and modest activity of the 12-carbon lauric acid – a constituent
of virgin coconut oil - against C. difficile has been reported
(Shilling et al., 2013; Yang et al., 2017). Exposure of C. difficile
cells to lauric acid leads to oxidative damage and cell lysis at
higher concentrations (Shilling et al., 2013; Yang et al., 2017).
Interestingly, orogastric pre-treatment with lauric acid decreased
symptoms in a mouse model of CDI. However, at present it
is unclear if these effects are due to an antimicrobial effect on
C. difficile cells or due to an effect on the host (Yang et al., 2017).
In total, a causal relationship between SCFA and MCFA levels
and C. difficile pathogenesis remains doubtful. Though a role for
these compounds in donor material seems plausible, we expect
that an analysis of fatty acid composition will potentially only
be informative when placed in the context of the microbial
composition and other variables.
BIOLOGICAL WARFARE
Other species of the microbial community not only interfere
with C. difficile by competing for, or cross-feeding on, nutrients.
Many bacterial species are known to produce antimicrobial
compounds that allow the elimination of competitors (Tracanna
et al., 2017). It is conceivable that the microbiota transferred by
FMT produces specific bacteriocins that kill C. difficile (Khoruts
and Sadowsky, 2016) (Figure 1D). Bacteriocins are proteinaceous
antimicrobial compounds and are synthesized in many bacteria
by ribosomes during translation (Le Lay et al., 2016). Their
inhibitory activity may be small-spectrum or broad-spectrum and
there are bactericidal and bacteriostatic bacteriocins. In general,
their activity is directed against bacteria that are phylogenetically
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close to the producing bacteria (Tagg et al., 1976). Some of
the antimicrobial peptides that target C. difficile are discussed
below.
Thuricin CD is a two-component bacteriocin, consisting of
peptides Trn-α and Trn-β, produced by Bacillus thuringiensis
DPC 6431, a bacterium derived from a human fecal sample (Rea
et al., 2010; Sit et al., 2011). It displays a narrow spectrum of
activity against mainly spore-forming gram-positive bacteria of
the class Clostridia and Bacilli. All C. difficile isolates tested were
sensitive to supernatants of B. thuringiensis DPC 6431, including
the epidemic PCR ribotype 027 NAP1. In an ex vivo distal colon
model, thuricin CD showed similar efficacy as metronidazole
(Rea et al., 2010) and vancomycin (Rea et al., 2011).
Nisin is a bacteriocin with broad antimicrobial activity against
a wide range of gram-positive bacteria (Lubelski et al., 2008). It
can be isolated from the known gut residents such as Blautia
obeum A2-162 (Hatziioanou et al., 2017) and species that
can proliferate in conditions that resemble the gut, including
Lactococcus lactis UL719 (Le Lay et al., 2015). In vitro studies
show that nisin can inhibit spore germination and vegetative
growth of C. difficile (Le Lay et al., 2016). In a human colon
model, L. lactis UL719 did not significantly alter the microbiota
composition and was not effective against C. difficile, likely
because nisin produced in vivo does not reach inhibitory levels
(Le Lay et al., 2015).
Lactobacillus reuteri carrying the pocR gene converts glycerol
to reuterin, a broad-spectrum antimicrobial compound (Spinler
et al., 2017). Reuterin induces oxidative stress, most likely
by modifying thiol groups (Schaefer et al., 2010). Reuterin
production increases in L. reuteri upon interaction with other
bacteria (Schaefer et al., 2010). Co-delivery of L. reuteri and
glycerol was effective and decreased the abundance of C. difficile
relative to the bacterial load in fecal mini-bioreactor arrays
pre-treated with antibiotics, without significantly affecting the
microbial composition, whereas reuterin, L. reuteri or glycerol
alone did not achieve this effect. This indicates that viable
L. reuteri, substrate and active reuterin production is required for
growth inhibition of C. difficile (Spinler et al., 2017).
Other antimicrobial compounds with activity against
C. difficile, alone or in combination, include enterococcal
durancin (Hanchi et al., 2017), formicin from Bacillus
paralicheniformis (Collins et al., 2016), microbisporicin from
the actinomycete Microbispora (Castiglione et al., 2008), and the
lactococcal lacticin 3147 (Rea et al., 2007).
The potential for members of the microbiota to inhibit
C. difficile is underscored by the fact that the clinically used
therapeutic fidaxomicin, as well as the pre-clinical compound
surotomycin were identified as natural products (Kociolek and
Gerding, 2016). Fidaxomicin is produced by the actinomycete
Dactylosporangium aurantiacum subspecies hamdenesis as a
byproduct of fermentation. It prevents transcription by inhibiting
bacterial RNA polymerase and is bactericidal against C. difficile.
Fidaxomicin is non-inferior to oral vancomycin in clinical
response and superior to oral vancomycin in reducing recurrent
CDI (Louie et al., 2011; Cornely et al., 2012). Surotomycin,
a cyclic lipopeptide antibiotic with a core derived from
Streptomyces roseosporus, acts on the membrane stability
of C. difficile, both in logarithmic and stationary phases
(Knight-Connoni et al., 2016). It has a low oral absorption
that allows high concentrations in the gastrointestinal tract
to be achieved. Despite promising phase II results, phase III
studies found the compound to be inferior to vancomycin
(Boix et al., 2017). Both fidaxomicin and surotomycin claim a
minimal impact on the gut microbiota (Kociolek and Gerding,
2016).
In addition to antimicrobial compounds produced by other
members of the microbiota, the lumen of the colon also
contains host-defense molecules that might play a role in
CDI progression and pathogenesis (Figure 1D). These include
defensins, cathelicidins such as LL-37 and lysozyme (McQuade
et al., 2012). Defensins (α-defensins: HD5-6 and HNP1-4;
β-defensins: HBD1-4) are small cationic peptides derived from
intestinal Paneth cells, neutrophils or epithelial cells (Nuding
et al., 2014). The human cathelicidin LL-37 is released upon
cleavage of the precursor hCAP-18, which is produced in
epithelial cells and some immune cells (Nuding et al., 2014).
Lysozyme hydrolyses peptidoglycan bonds between N-acetyl-
glucosamine and N-acetylmuramic acid and as a result the
bacteria become sensitive to lysis (Chai et al., 2015).
Defensins and LL-37 were tested alone or in combination with
antibiotics (tigecycline, moxifloxacin, piperacillin-tazobactam,
and meropenem) against toxigenic and non-toxigenic C. difficile
strains (Nuding et al., 2014). The antimicrobial peptides alone
demonstrated some antimicrobial activity against C. difficile, but
when combined, an additive effect was observed (Nuding et al.,
2014). Certain treatments resulted in increased toxin release,
presumably due to lysis of C. difficile (Nuding et al., 2014). This
suggests that antimicrobial peptides alone or in combination with
antibiotics not only exert a positive effect on CDI (clearance
of C. difficile), but could potentially also worsen symptoms
(by inducing more inflammation). Interestingly, α-defensins
(HNP-1, HNP-3, and HD-5) appear to inhibit toxin B, but
not toxin A, activity. The inhibition was dose dependent and
reversible. β-defensins and LL-37 did not inhibit toxin A or
toxin B (Giesemann et al., 2008). Similarly, LL-37, or the murine
homolog cRAMP, can modulate the inflammatory response to
toxins in a mouse model of infection (Hing et al., 2013).
Lysozyme can act synergistically with bacterial antimicrobial
peptides, as shown for nisin (Chai et al., 2015).
The effectiveness of human defense molecules might depend
on the C. difficile isolate as variation in susceptibility to LL-37 was
observed between C. difficile strains, with epidemic ribotype 027
strains being less susceptible than non-RT 027 strains (McQuade
et al., 2012). C. difficile is capable of mounting a response to
antimicrobial peptides and lysozyme (McBride and Sonenshein,
2011a,b; Hastie et al., 2014), but the contribution of these
mechanisms to the observed variability is unknown.
There is very limited data on the role that defense molecules
might play in FMT. A study describing the colonoscopic FMT
for the treatment of CDI reported that LL-37 levels in plasma
were significantly increased 3 months post-FMT, compared
to pre-FMT and 3-weeks post-FMT (Konturek et al., 2016).
As cathelicidins are important in preventing intestinal barrier
dysfunction, this was taken as an indication of recovery from
Frontiers in Microbiology | www.frontiersin.org 7 June 2018 | Volume 9 | Article 1242
fmicb-09-01242 June 8, 2018 Time: 18:58 # 8
Baktash et al. Mechanisms of FMT in CDI
CDI-damage (Konturek et al., 2016). It does indicate however,
that healthy subjects likely demonstrate higher levels of LL-37
than CDI patients. It has been demonstrated that endogenous
levels of cathelicidins are likely insufficient to maintain barrier
function, but that high levels of exogenously provided LL-37 or
cRAMP can reduce CDI symptoms in a mouse model (Hing et al.,
2013).
Overall, we believe that antimicrobial peptides – whether
derived from the microbiota or the host – have the potential to
contribute to the efficacy of FMT. However, a clear correlation
between FMT success and levels of these compounds in donor
material remains to be established.
BACTERIOPHAGES
Above we discussed how inter-bacterial competition and host-
defense can modulate the gut microbiota. However, another
level of complexity exists in the form of bacteriophages
(Figure 1D).
Bacteriophages are viruses, composed of proteins that
encapsulate a DNA or RNA genome, and replicate within bacteria
and archaea (Salmond and Fineran, 2015; Ofir and Sorek, 2018).
Binding of bacteriophages to specific receptors on the bacterial
cell determines their host range (Dowah and Clokie, 2018). Lytic
phages infect, multiply in and lyse bacterial cells. In contrast,
lysogenic phages can integrate into host DNA and replicate along
with it, or become established as a plasmid without immediate
lysis of the host (Salmond and Fineran, 2015; Ofir and Sorek,
2018). Phage exposure can not only affect the composition of the
microbiota, but may also alter different phenotypes, including
virulence and biofilm formation (Mirzaei and Maurice, 2017;
Fernandez et al., 2018).
Prophages and phages have been found in pathogenic
clostridia (Hargreaves and Clokie, 2014; Fortier, 2017). For
instance, neurotoxin and α-toxin (TcnA) of Clostridium
botulinum types C and D and Clostridium novyi, respectively, are
encoded on prophages. In C. difficile, prophage carriage is high
and one particular strain has been found to contain binary toxin
on a prophage (Hargreaves et al., 2013; Fortier, 2017; Riedel et al.,
2017). Phages known to infect C. difficile belong to the order
of Caudovirales and, more specifically, the families Myoviridae
and Siphoviridae (Hargreaves and Clokie, 2015; Ramirez-Vargas
et al., 2018). As observed for other viruses, (pro)phages have
been found to alter (virulence) gene expression in C. difficile
(Goh et al., 2005; Govind et al., 2009; Sekulovic et al., 2011;
Hargreaves et al., 2014b; Sekulovic and Fortier, 2015). CRISPR
(clustered regularly interspaced short palindromic repeats)-Cas
(CRISPR-associated) adaptive immune systems are widespread
among bacteria and archaea. Recent studies have shown that
these systems have minimal long-term evolutionary effects in
limiting horizontal gene transfer (Pawluk et al., 2018). C. difficile
contains a CRISPR-Cas system that provides defense against
plasmid DNA and bacteriophages, as has been demonstrated in
reference strain 630 and the epidemic ribotype 027 strain R20291
(Hargreaves et al., 2014a; Boudry et al., 2015; Andersen et al.,
2016).
Phages are induced during CDI as sterile filtrates of CDI
patients contained multiple phages (Meessen-Pinard et al.,
2012). CDI patients display a higher abundance of Caudovirales
than healthy household controls, and lower diversity, richness
and evenness (Zuo et al., 2018). Moreover, treatment with
antibiotics such as quinolones induced prophage mobility in vitro
(Meessen-Pinard et al., 2012), as has also been observed by
others (Modi et al., 2013). It therefore seems likely that both
the virulence potential and horizontal gene transfer could be
affected under conditions that sustain C. difficile expansion and
pathogenesis.
Phages can be employed to treat bacterial infectious diseases
(Abedon, 2017). At a time of growing antibiotic resistance in
bacteria and the resulting restrictions on the use of antibiotics,
bacteriophages can provide an alternative means of eliminating
pathogens. Is it possible to use bacteriophages to treat CDI?
Phage 8CD27 demonstrates a significant reduction in C. difficile
cell numbers and toxin production in an in vitro human colon
model of CDI, without major effects on other members of
the microbiota (Meader et al., 2010; Meader et al., 2013).
Combinations of phage in batch cultures resulted in a 6-log
reduction of C. difficile ribotype 014/020 (Nale et al., 2018), a
type commonly identified amongst clinical isolates (Bauer et al.,
2011), and were found to be able to penetrate established biofilms
(Nale et al., 2016a). Though resistance to individual phages can
be problematic, the resistant C. difficile remain susceptible to
other phages (Nale et al., 2016b). Results obtained in animal
models largely mirror the in vitro results. In hamsters, the
administration of optimized phage cocktails resulted in reduced
C. difficile colonization and recovery of free phage from the
lumen of the cecum and the colon; moreover, pre-treatment with
a phage cocktail delayed the onset of disease (Nale et al., 2016b).
In a wax moth (Galleria mellonella) model, a phage cocktail
was effective alone, or as adjunct therapy to vancomycin (Nale
et al., 2016a). Besides live phages, phage-derived proteins are also
explored as alternatives for treatment (Mayer et al., 2011; Kirk
et al., 2017). Notably, phages demonstrate increased virulence
toward bacteria in the presence of eukaryotic cells (Shan et al.,
2018).
There are a limited number of studies that investigate phages
during FMT treatment. A case study of a recurrent CDI
patient demonstrated donor-similar characteristics of the virome
following FMT (Broecker et al., 2017). Similarly, after FMT
of a single healthy donor to three ulcerative colitis patients,
donor-similar viral sequences were readily detected (Chehoud
et al., 2016). Interestingly, temperate phages such as Siphoviridae
were more likely to be transferred, suggesting that transfer
or establishment may be dependent on lysogeny (Chehoud
et al., 2016). An ultra-deep metagenomic sequencing study of
viral transfer during FMT analyzed longitudinal samples of
9 CDI patients receiving FMT, and 5 receiving vancomycin
treatment (Zuo et al., 2018). FMT treatment decreased the
absolute abundance of Caudovirales, and treatment response
correlated with the presence of donor-derived phage among
those that were detected (Zuo et al., 2018). This suggests a
role for Caudovirales bacteriophage in the efficacy of FMT.
This is supported by a recent study where sterile (bacteria-free)
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fecal filtrates were transferred to 5 patients with symptomatic
chronic-relapsing CDI (Ott et al., 2017). The transfer of the
filtrates, that showed a complex signature of bacteriophages,
prevented recurrent CDI in all 5 patients for a minimum period
of 6 months.
Taken together, it appears that the concept of CDI-
predisposing dysbiosis, as a result of for instance antimicrobial
treatment, could be extended to include bacteriophage and
that phage therapy could be useful in the treatment of disease
(Manrique et al., 2017).
OTHERS
So far, this review has focused on variables with a strong
biotic component. However, abiotic factors, including metal
availability, are known to affect infectious diseases (Fischer
Walker and Black, 2004). Several secreted and surface-exposed
proteins of C. difficile contain zinc as a co-factor, prompting an
investigation of the effects of dietary zinc in a mouse model of
CDI (Zackular et al., 2016). It was reported that mice on a high-
zinc diet displayed a reduced diversity of their gut microbiota,
and a concomitant reduction in threshold of antibiotics needed
to induce CDI. Furthermore, consistent with a role in Toxin A
auto-processing (Chumbler et al., 2016), CDI was exacerbated
by an increased toxin activity in mice on a high-zinc diet. The
mechanisms by which excess Zn alters the structure of the
gut microbiota is unknown, but the authors postulate that it
is a combination of several factors and consider metal toxicity
to specific bacterial species as one of them (Zackular and
Skaar, 2018). Human calprotectin is a zinc binding protein with
broad activity against bacterial pathogens (Zackular et al., 2015).
Consistent with a role in the innate immune response against
C. difficile, calprotectin levels correlate with adverse outcome in
CDI (Rao et al., 2016) and calprotectin-deficient mice show more
severe CDI (Zackular et al., 2016).
Other metals have also been implicated in CDI. Divalent
calcium ions are important for efficient germination of
C. difficile and patients with inefficient calcium adsorption have
a predisposition for CDI (Kochan et al., 2017).
Though the effects of levels of metals and metal-binding
proteins such as calprotectin have not been systematically
investigated, there is an intriguing possibility of modulating the
efficacy of FMT by adjusting metal availability.
CONCLUSION
Many studies have shown that FMT is an effective treatment in
patients with recurrent CDI (van Nood et al., 2013; Moayyedi
et al., 2017; Quraishi et al., 2017; Terveer et al., 2017a; Ooijevaar
et al., 2018). In the future, FMT may find other applications
beyond C. difficile infections (Bakker and Nieuwdorp, 2017).
However, since systematic investigations of FMT are relatively
new, the mechanisms underlying the efficacy remain largely
unknown. We expect that different mechanisms may play a role
for other diseases than CDI.
We believe that it is unlikely that a single factor is responsible
for the efficacy of FMT; the possible mechanisms examined in this
review indicate that although individual variables evidently can
modulate CDI, the mechanism of FMT is likely multifactorial.
Indeed, FMT was found to restore both SCFA levels and bile
acid metabolism (Seekatz et al., 2018). It should be noted that
the gut microbiota is both influenced by, and influences, levels
of compounds such as bile acids, short chain fatty acids and
nutrients, complicating analyses of cause and effect (Seekatz and
Young, 2018).
Current evidence suggests that part of the success of FMT
can be attributed to the reconstitution of a robust and diverse
microbiota of the gut (Lawley et al., 2012; van Nood et al.,
2013). These findings were challenged, however, by the recent
report that sterile filtrates were effective in treating recurrent
CDI (Ott et al., 2017). It should be noted that these results have
not been replicated yet in a randomized control trial, and are
in contradiction with a study in mice that shows that transfer
of buffer, fecal filtrate, a solution of short chain fatty acids or
a single bacterial strain is unable to clear a C. difficile infection
(Lawley et al., 2012). Perhaps non-bacterial components of a
fecal filtrate are capable of transiently suppressing C. difficile
growth, while allowing regrowth of a seeding population of a
diverse microbiota that is still present in the patient’s gut. The
use of sterile fecal filtrates might be beneficial for certain patient
groups.
Fecal microbiota transplantation leads to a fast improvement
of symptoms and generally resolves CDI within days. An
open question is whether such a short period is sufficient for
stable engraftment of the transplanted microbial community
in the host gut, with the concomitant eubiosis that is believed
to suppress C. difficile. With regard to the mechanisms
described in this review, such a fast improvement upon
FMT appears most compatible with agents that directly
affect C. difficile viability, possibly penetrating biofilms or
pseudomembranes, such as antimicrobials or phage (Ott
et al., 2017). Alternatively, it may be the result of direct
suppression of inflammation, for instance through the action
of defensins on toxin activity (Giesemann et al., 2008), or yet
undefined compounds affecting host pathways underlying
the inflammatory response (Cowardin and Petri, 2014;
Chandrasekaran and Lacy, 2017). A crucial aspect missing
from our current understanding of FMT is the role that host
factors, both genetic and immunological, play in treatment
efficacy.
We expect that comprehensive investigations – including
the bacterial and bacteriophage composition, metabolites and
small molecules – of donor material, as well as fecal contents
of patients before and after FMT, will reveal how these are
connected and will aid in the rational design of a synthetic donor
infusion.
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